Most write-ups of tesamorelin stop at the waistline. But the compound has a second, much quieter research thread — brain function — and it now has two human datasets pointing in different directions. A 2012 placebo-controlled trial in older adults reported improved executive function. A phase 2 trial published in 2025 in people with HIV and abdominal obesity found no significant between-group cognitive difference. If you're searching "tesamorelin research" and running into confident claims about memory and focus, this is the gap those claims are papering over.

Here we'll walk through what each trial actually did, why they aren't a clean replication pair, and where tesamorelin Australia access stands — because the regulatory answer here is unusually short.

What is tesamorelin, and why would anyone test it on cognition?

Tesamorelin is a stabilised analogue of human growth hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it prompts the pituitary to release its own GH in pulses, which in turn raises IGF-1. It's been FDA-approved since 2010 (as Egrifta) for one narrow indication only: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Nothing else.

The cognitive rationale is indirect. GH and IGF-1 decline with age, and that decline runs alongside age-related changes in executive function. GHRH analogues offered a way to nudge the axis upward while preserving the pulsatile pattern of natural secretion — theoretically gentler than exogenous GH. That's a mechanistic hypothesis, not a finding, and it's worth holding it loosely.

You can read the broader profile on our tesamorelin page and see how it sits against other compounds in the peptides section.

The 2012 trial: a real positive result, in a specific population

The 2012 study (Baker and colleagues, Archives of Neurology) is the strongest cognitive data tesamorelin has. Design details matter:

  • 152 adults aged 55–87 randomised; 137 completed — 76 cognitively healthy, 61 with mild cognitive impairment (MCI)
  • Tesamorelin 1 mg/day or matched placebo, self-injected about 30 minutes before bed
  • 20 weeks of treatment, with testing at baseline, week 10 and week 20, plus a washout assessment
  • Double-blind and placebo-controlled

Results favoured tesamorelin on executive function measures, with a weaker signal on verbal memory, and the effect appeared in both the healthy and MCI groups. The trial report also noted IGF-1 rising sharply from baseline while remaining inside the normal physiological range.

Two honest caveats. First, this is a single trial of 137 completers over 20 weeks — a proof-of-concept, not a treatment case. Second, the cognitive endpoints were composite test scores, not clinical outcomes like progression to dementia. Nobody has replicated it in an equivalent population in the 14 years since.

The 2025 phase 2: the adjacent test, and what it found

The nearest thing to a follow-up was published in The Journal of Infectious Diseases in 2025, from a trial sponsored by the University of California, San Diego and funded by the US National Institute on Aging (registered as NCT02572323 — a real academic sponsor, worth checking given how many fictional peptide records now sit on registries).

It enrolled 73 people with virally suppressed HIV and abdominal obesity, randomised 3:2 to tesamorelin 2 mg daily or standard of care for six months. Primary endpoint: change in neurocognitive performance at six months.

The numbers:

  • Tesamorelin arm: mean change 0.146 (95% CI −0.002 to 0.294), P = 0.060
  • Standard-of-care arm: mean change 0.103 (95% CI −0.095 to 0.301), P = 0.295
  • Between-group difference: P = 0.673 — not significant

That last line is the one to keep. The tesamorelin arm's near-threshold improvement is the figure that gets quoted in isolation, but the control arm improved too, and the comparison between them was nowhere near significant. In cognitive testing, repeated exposure to the same tests produces practice effects, and this trial was open-label — no blinding, no placebo injection — so expectancy runs in the same direction. A within-arm trend under those conditions tells you very little.

The body-composition endpoint behaved differently. Waist circumference fell more on tesamorelin than standard of care, a median difference of −2.7 cm (P = 0.015). Same trial, same participants: the fat endpoint separated, the cognitive endpoint didn't.

Why this isn't a straight replication failure

It's fair to note the two trials tested different questions. The 2012 cohort was older adults with MCI or healthy ageing; the 2025 cohort was people with HIV, abdominal obesity and neurocognitive impairment with a different underlying biology. The doses differed too — 1 mg at bedtime versus 2 mg daily — and the higher dose didn't produce a bigger cognitive effect. So the 2025 result doesn't overturn 2012; it declines to extend it. What we're left with is one unreplicated positive in one population, and one null between-group comparison in another.

The responsible summary: tesamorelin's cognitive effects in humans remain unproven.

Tesamorelin Australia: is tesamorelin legal in Australia?

The regulatory picture is the clearest part of this story.

Tesamorelin is not on the Australian Register of Therapeutic Goods (ARTG). There is no TGA-approved tesamorelin product in Australia for any indication — not lipodystrophy, and certainly not cognition. A sponsor application was submitted to the European Medicines Agency and then withdrawn before approval in 2012, so it has never been EMA-approved either. Its only approval anywhere of consequence is the FDA's, and that is limited to HIV-associated lipodystrophy.

There's a plausible commercial reason for the Australian absence: the lipodystrophy syndrome tesamorelin was developed for was largely driven by older antiretroviral regimens. With modern ART, that clinical population in Australia is small — thin ground for an ARTG registration dossier.

Practically, that means any Australian supply sits outside a registered product: unapproved-goods pathways such as the Special Access Scheme or Authorised Prescriber, at a prescriber's discretion. Vials sold online labelled "research use only" are not registered therapeutic goods, carry no assurance of identity or purity, and importing them for personal use is not a legal workaround. We don't publish sourcing information.

Athletes should also note that GHRH analogues — tesamorelin included — are prohibited by WADA at all times, in and out of competition. A cognitive rationale is not an exemption.

What would actually settle this

A blinded, placebo-controlled trial in a defined cognitive population, powered for a between-group difference, with a pre-registered primary endpoint and a control for practice effects. That is precisely the design the 2012 trial used and the 2025 trial did not. Until something like it runs, "tesamorelin for memory" is a hypothesis with one supportive trial and one adjacent null — not a finding.

Want the next tesamorelin readout flagged as it lands? Join the free updates list.

FAQ

Does tesamorelin improve memory or cognition?

The evidence is unsettled. A 2012 placebo-controlled trial in 137 older adults found improved executive function over 20 weeks, but a 2025 phase 2 trial in people with HIV and abdominal obesity found no significant between-group cognitive difference (P = 0.673). It remains unproven in humans.

Is tesamorelin legal in Australia?

Tesamorelin is not on the ARTG, so there is no TGA-approved product in Australia. Access would only occur via unapproved-goods pathways such as the Special Access Scheme or Authorised Prescriber, at a prescriber's discretion. "Research use only" vials are not registered therapeutic goods.

What is tesamorelin actually approved for?

Only HIV-associated lipodystrophy — reduction of excess abdominal fat in adults with HIV — under the FDA approval granted in 2010. The European application was withdrawn before approval in 2012, and there is no Australian registration.

Is tesamorelin banned in sport?

Yes. WADA prohibits growth hormone-releasing hormone analogues at all times, both in and out of competition, and tesamorelin falls in that class.

Sources

This article is independent information, not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, was never EMA-approved, and is not on the ARTG in Australia; any cognitive use is investigational. Speak to a qualified Australian health professional about your own situation.